Cisplatin increases TNF-α mRNA stability in kidney proximal tubule cells

Renal Failure

Volumn 28, Issue 7, 2006, Pages 583-592

  Ramesh, Ganesan ^a   Reeves, W Brian ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Acute renal failure; Cisplatin; Kidney; MAP kinases; Proximal tubule; Renal epithelial cells; RNA stability; TNF

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; CELL PROTEIN; CISPLATIN; CYCLOHEXIMIDE; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN D; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PROTEIN P42; PROTEIN P44; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA;

3' UNTRANSLATED REGION; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; DRUG EFFECT; ENZYME ACTIVITY; INHIBITION KINETICS; KIDNEY CELL CULTURE; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN SYNTHESIS; RNA STABILITY;

ACUTE KIDNEY INJURY; ANIMALS; CELL CULTURE TECHNIQUES; CELLS, CULTURED; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITHELIAL CELLS; KIDNEY FAILURE, ACUTE; KIDNEY TUBULES, PROXIMAL; MICE; MITOGEN-ACTIVATED PROTEIN KINASES; POLYMERASE CHAIN REACTION; RNA STABILITY; RNA, MESSENGER; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33750075131     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.1080/08860220600843839     Document Type: Article

References (57)

1. 1. J. Immunol. 2002;168:3065-3071.
2. Aggarwal BB, Samanta A, Feldmann M. TNFα. In: Oppenheim JJ, Feldmann M, eds. Cytokine Reference. San Diego, Calif.: Academic Press, 2001, pp. 413-434.
3. Keilar ML, Jeyarajah DR, Zhou XJ, Lu CY. Docosahexanoic acid ameliorates murine ischemic acute renal failure and prevents increases in mRNA abundance for both TNFα and inducible nitric oxide synthase. J. Am. Soc. Nephrol. 2003;14:389-C396.
4. Donnahoo K, Meng X, Ayala A, Cain M, Harken A, Meldrum D. Early kidney TNF-α expression mediates neutrophil infiltration and injury after renal ischemia-reperfusion. Am. J. Physiol. 1999;277:R922-CR929.
5. Daemen M, Ven M, Heineman E, Buurman W. Involvement of endogenous interleukin-10 and tumor necrosis factor-a in renal ischemia-reperfusion injury. Transplantation 1999;67(6):792-799.
6. Cunningham PN, Dyanov HM, Park P, Wang J, Newell KA, Quigg RJ. Acute renal failure in endotoxemia is caused by TNF acting directly on TNF receptor-1 in kidney. Journal of Immunology. 2002;168(11):5817-C5823.
7. Shulman LM, Yuhas Y, Frolkis I, Gavendo S, Knetch A, Eliahou HE. Glycerol induced ARF in rats is mediated by tumor necrosis factor a. Kidney Int. 1993;43:1397-C1401.
8. Deng J, Kohda Y, Chiao H, Wang Y, Hu X, Hewitt S, Miyaja T, McLeroy P, Nibhanupudy B, Li S, Star R. Interleukin-10 inhibits ischemic and cisplatin-induced acute renal injury. Kidney Int. 2001;60:2118-2128.
9. Ramesh G, Reeves WB. TNF-α mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J. Clin. Invest. 2002;110:835-842.
10. Hahn AB, Kasten-Jolly JC, Constantino DM, Graffunder E, Singh TP, Shen GK, Conti DJ. TNF-α, IL-6, IFN -g, and IL-10 gene expression polymorphisms and the IL-4 receptor a-chain variant Q576R: Effects on renal allograft outcome. Transplantation. 2001;72:660-665.
11. Al-Lamki R, Wang J, Skepper J, Thiru S, Pober J, Bradley J. Expression of tumor necrosis factor receptors in normal kidney and rejecting renal transplants. Lab. Invest. 2001;81(11):1503-1515.
12. Guo G, Morrissey J, McCracken R, Tolley T, Klahr S. Role of TNFR1 and TNFR2 receptors in tubulointerstitial fibrosis of obstructive nephropathy. Am. J. Physiol.: Renal Physiol. 1999;277:F766-F772.
13. Guo G, Morrissey J, McCracken R, Tolley T, Liapis H, Klahr S. Contributions of angiotensin II and tumor necrosis factor-a to the development of renal fibrosis. Am. J. Physiol. Renal Physiol. 2001;280:F777-F785.
14. Honkanen E, Willebrand E, Teppo A, Tornroth T, Riska C. Adhesion molecules and urinary tumor necrosis factor-a in idiopathic membranous glomerulonephritis. Kidney Int. 1998;53:909-917.
15. Kalantrinia K, Awad AS, Siragy HM. Urinary and renal interstitial concentrations of TNF-α increase prior to the rise in albuminuria in diabetic rats. Kidney Int. 2003;64:1208-1213.
16. Timoshanko JR, Sedgwick JD, Holdsworth SR, Tipping PG. Intrinsic renal cells are the major source of tumor necrosis factor contributing to renal injury in murine crescentric glomerulonephritis. J. Am. Soc. Nephrol. 2003;14:1785-1793.
17. Tsuruya K, Ninomiya T, Tokumoto M, Hirakawa M, Matsutani K, Taniguchi M, Fukuda K, Kanai H, Kishihara K, Hirakata H, Iida M. Direct involvement of the receptor-mediated apoptotic pathways in cisplatin-induced renal tubular cell death. Kidney Int. 2003;63:72-82.
18. Ramesh G, Reeves WB. TNFR2-mediated apoptosis and necrosis in cisplatin-induced acute renal failure. Am. J. Physiol: Renal Physiol. 2003;54:F610-F618.
19. Tsai E, Yie J, Thanos D, Goldfeld A. Cell-type-specific regulation of the human tumor necrosis factor alpha gene in B cells and T cells by NFATp and ATF-2/JUN. Mol. Cell. Biol. 1996;16(10):5232-5244.
20. Tsai E, Jain J, Pesavento P, Rao A, Goldfeld A. Tumor necrosis factor alpha gene regulation in activated t cells involves ATF-2/Jun and NFATp. Mol. Cell. Biol. 1996;16:459-67.
21. Yao J, Mechman N, Edgington T, Fan S. Lipopolysaccharide induction of the tumor necrosis factor-a promoter in human monocytic cells. J. Biol. Chem. 1997;272 (28):17795-17801.
22. Zhang T, Kruys V, Huez G, Gueydan C. AU-rich element-mediated translational control: complexity and multiple activities of trans-activating factors. Biochemical Society Transactions. 2002;30(Pt. 6):952-958.
23. Brook M, Sully G, Clark AR, Saklatvala J. Regulation of tumour necrosis factor α mRNA stability by the mitogen-activated protein kinase p38 signalling cascade. FEBS Letters 2000;483 (1):57-61.
24. Raghavan A, Ogilvie RL, Reilly C, Abelson ML, Raghavan S, Vasdewani J, Krathwohl M, Bohjanen PR. Genome-wide analysis of mRNA decay in resting and activated primary human T lymphocytes. Nucl. Acids. Res. 2002;30(24):5529-5538.
25. Carballo E, Lai W, Blackshear P. Feedback inhibition of macrophage tumor necrosis factor-a production by tristetraprolin. Science 1998;281:1001-1005.
26. Bollig F, Winzen R, Gaestel M, Kostka S, Resch K, Holtmann H. Affinity purification of ARE-binding proteins identifies poly(A)-binding protein 1 as a potential substrate in MK2-induced mRNA stabilization. Biochem. Biophys. Res. Commun. 2003;301:665-670.
27. Dumitru CD, Ceci JD, Tsatsanis C, Kontoyiannis D, Stamatakis K, Lin J-H, Copeland NG, Kollias G, Tsichlis PN. TNF-α induction by LPS is regulated postranscriptionally via a Tpl2/ERK-dependent pathway. Cell 2000;103:1071-1083.
28. Rousseau S, Morrice N, Peggie M, Campbell DG, Gaestel M, Cohen P. Inhibition of SAPK2a/p38 prevents hnRNP A0 phosphorylation by MAPKAP-K2 and its interaction with cytokine mRNAs. EMBO J. 2002;21(23):6505-6514.
29. Persons D, Yazlovitskaya E, Pelling J. Effect of extracellular signal-regulated kinase on p53 accumulation in response to cisplatin. J. Biol. Chem. 2000;275:35778-35785.
30. Wang X, Martindale J, Holbrook N. Requirement for ERK activation in cisplatin-induced apoptosis. J. Biol. Chem. 2000;275:39435-39443.
31. Sanchez-Perez I, Martinez-Gomariz M, Williams D, Keyse S, Perona R. CL100/MKP-1 modulates JNK activation and apoptosis in response to cisplatin. Oncogene. 2000;26:5142-5152.
32. Ramesh G, Reeves WB. Salicylate reduces cisplatin nephrotoxicity by inhibition of tumor necrosis factor-a. Kidney Int. 2004;65:490-498.
33. Ramesh G, Reeves WB. p38 MAP kinase inhibition ameliorates cisplatin nephrotoxicity in mice. Am. J. Physiol. Renal Physiol. 2005;289(1):F166-F174.
34. Ye J, Zeidler P, Young S, Martinez A, Robinson V, Jones W, Baron P, Shi X, Castranova V. Activation of mitogen-activated protein kinase p38 and extracellular signal-regulated kinase is involved in glass fiber-induced tumor necrosis factor-a production in macrophages. J. Biol. Chem. 2001;276(7):5360- 5367.
35. Meldrum K, Meldrum D, Hile K, Yerkes E, Ayala A, Cain M, Rink R, Casale A, Kaefer M. p38 MAPK mediates renal tubular cell TNF-α production and TNF-α dependent apoptosis during simulated ischemia. Am. J. Physiol. Cell Physiol 2001;281:C563-C70.
36. Roulston A, Reinhard C, Amiri P, Williams L. Early activation of c-Jun N-terminal kinase and p38 kinase regulate cell survival in response to tumor necrosis factor a. The Journal of Biological Chemistry. 1998;273(17):10232- 10239.
37. Jupp O, McFarlane S, Anderson H, Littlejohn A, Mohamed A, MacKay R, Vandenabeele P, MacEwan D. Type II tumour necrosis factor-x receptor (TNFR2) activates c-Jun N-terminal kinase (JNK) but not mitogen-activated protein kinase (MAPK) or p38 MAPK pathways. Biochemical Society. 2001;359:525-535.
38. English JM, Cobb MH. Pharmacological inhibitors of MAPK pathways. Trends in Pharmacol. Sci. 2002;23:40-45.
39. Caput D, Beutler B, Hartog K, Thayer R, Brown-Shimer S, Cerami A. Identification of a common nucleotide sequence in the 3′-untranslated region of mRNA molecules specifying inflammatory mediators. Proc. Natl. Acad. Sci. USA. 1986;83:1670-1674.
40. Saito K, Chen S, Piecyk M, Anderson P. TIA-1 regulates the production of tumor necrosis factor alpha in macrophages, but not in lymphocytes. Arthritis & Rheumatism. 2001;44(12):2879-2887.
41. Gueydan C, Droogmans L, Chalon P, Huez G, Caput D, Kruys V. Identification of TIAR as a protein binding to the translational regulatory AU-rich element of tumor necrosis factor-a mRNA. J. Biol. Chem. 1999;274:2322-2326.
42. Anderson P, Kedersha N. Visibly stressed: the role of eIF2, TIA-1, and stress granules in protein translation. Cell Stress & Chaperones. 2002;7(2):213-221.
43. Mahtani KR, Brook M, Dean JLE, Sully G, Saklatwala J, Clark AR. Mitogen-activated protein kinase p38 controls the expression and posttranslational modification of tristetraprolin, a regulator of tumor necrosis factor alpha mRNA stability. Mol. Cell. Biol. 2001;21:6461-6469.
44. Laroia G, Sarkar B, Schneider RJ. Ubiquitin-dependent mechanism regulates rapid turnover of AU-rich cytokine mRNAs. Proc. Natl. Acad. Sci. USA. 2002;99(4):1842-1846.
45. Lebwohl D, Canetta R. Clinical development of platinum complexes in cancer therapy: an historical perspective and an update. Eur. J. Cancer. 1998;34:1522-1534.
46. Ries F, Klastersky J. Nephrotoxicity induced by cancer chemotherapy with special emphasis on cisplatin toxicity. Am. J. Kidney Dis. 1986;13:368-379.
47. Tsuruya K, Tokumoto M, Ninomiya T, Hirakawa M, Matsutani K, Taniguchi M, Fukuda K, Kanai H, Hirakata H, Iida M. Antioxidant ameliorates cisplatin-induced renal tubular cell death through inhibition of death receptor-mediated pathways. Am. J. Physiol: Renal Physiol. 2003;285:F208-F218.
48. Means TK, Pavolvich RP, Roca D, Vermeulen MW, Fenton MJ. Activation of TNF-α transcription utilizes distinct MAP kinase pathways in different macrophage populations. J. Leukocyte Biol. 2000;67:885-893.
49. Shi L, Kishore R, McMullen MR, Nagy LE. Lipopolysaccharide stimulation of ERK1/2 increases TNF-α production via Egr-1. Am. J. Physiol.: Cell Physiol. 2002;282:C1205-C1211.
50. Neininger A, Kontoyiannis D, Kotlyarov A, Winzen R, Eckert R, Volk HD, Holtmann H, Kollias G, Gaestel M. MK2 targets AU-rich elements and regulates biosynthesis of tumor necrosis factor and interleukin-6 independently at different post-transcriptional levels. Journal of Biological Chemistry. 2002;277(5):3065-3068.
51. Nowak G. Protein kinase c-alpha and ERK1/2 mediate mitochondrial dysfunction, decreases in active NA+ transport, and cisplatin-induced apoptosis in renal cells. J. Biol. Chem. 2002;277(45):43377-43388.
52. Chen CY, Shyu AB. AU-rich elements: characterization and importance in mRNA degradation. Trends Biochem. Sci. 1995;20:465-470.
53. Kontoyiannis D, Pasparakis M, Pizarro TT, Cominelli F, Kollias G. Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies. Immunity. 1999;10:387-398.
54. Lewis T, Gueydan C, Huez G, Toulme J, Kruys V. Mapping of a minimal AU-rich sequence required for lipopolysaccharide-induced binding of a 55-kDa protein on tumor necrosis factor-a mRNA. J. Biol. Chem. 1998;273:13781-13786.
55. Peleg-Shulman T, Najajreh Y, Gibson D. Interactions of cisplatin and transplatin with proteins. Comparison of binding kinetics, binding sites and reactivity of the Pt-protein adducts of cisplatin and transplatin towards biological nucleophiles. J. Inorganic Biochem. 2002;91(1):306-311.
56. Shin JN, Seo YW, Kim M, Park S-Y, Lee M-J, Lee BR, Oh J-W, Seol D-W, Kim T-H. Cisplatin inactivation of caspases inhibits death ligand-induced cell death in vitro and fulminant liver damage in mice. J. Biol. Chem. 2005;280 (11):10509-10515.
57. Frevel MAE, Bakheet T, Silva AM, Hissong JG, Khabar KSA, Williams BRG. P38 mitogen-activated protein kinase-dependent and -independent signaling of mRNA stability of AU-rich element-containing transcripts. Mol. Cell. Biol. 2003;23(2):425-436.